Campbell & Co Investment Adviser’s Syndax Pharmaceuticals SNDX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-46,829	Closed	-$439K	–	1367
2025 Q2	$439K	Buy	+46,829	New	+$515K	0.03%	835
2024 Q3	–	Sell	-33,123	Closed	-$680K	–	1312
2024 Q2	$680K	Buy	+33,123	New	+$693K	0.06%	528
2020 Q1	–	Sell	-44,838	Closed	-$394K	–	452
2019 Q4	$394K	Buy	+44,838	New	+$329K	0.12%	315
2019 Q3	–	Sell	-39,372	Closed	-$367K	–	756
2019 Q2	$367K	Buy	+39,372	New	+$287K	0.17%	238

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Campbell & Co Investment Adviser's SNDX Position: Q3 2025 in Review

Campbell & Co Investment Adviser sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 46,829 shares — an estimated $439K sold.

Campbell & Co Investment Adviser first reported a position in SNDX in Q2 2019 and held it in 4 quarters. The position peaked at $680K in Q2 2024. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

Campbell & Co Investment Adviser reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 46,829 Syndax Pharmaceuticals shares in Q3 2025, an estimated $439K.
Campbell & Co Investment Adviser first reported a position in Syndax Pharmaceuticals in Q2 2019 and held it in 4 quarters.
Campbell & Co Investment Adviser's Syndax Pharmaceuticals position peaked at $680K in Q2 2024.
227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2025, filed 28 Oct 2025.